Luminex Corporation, a leading player in the biotechnology industry, is headquartered in the United States. Founded in 1995, the company has established itself as a pioneer in multiplexing technology, providing innovative solutions for the life sciences and diagnostics sectors. With a strong presence in North America and expanding operations globally, Luminex focuses on developing and manufacturing a range of products, including molecular diagnostics, immunoassays, and laboratory instruments. Luminex's core offerings, such as the xMAP® Technology and the ARIES® System, are distinguished by their ability to deliver rapid, accurate results across various applications, from infectious disease testing to personalised medicine. The company has achieved significant milestones, including numerous FDA approvals and partnerships that enhance its market position. Luminex continues to drive advancements in healthcare, making it a trusted name in the biotechnology landscape.
How does Luminex Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Luminex Corporation's score of 45 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Luminex Corporation, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of DiaSorin S.p.A., which may influence its climate commitments and reporting practices. As of now, Luminex has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate initiatives. The lack of specific emissions data and reduction initiatives suggests that Luminex is still in the early stages of formalising its climate strategy. Given its affiliation with DiaSorin S.p.A., any climate-related performance metrics or targets may be inherited from this parent company. However, specific details regarding DiaSorin's emissions or climate commitments have not been provided in the available data. In summary, Luminex Corporation's current climate commitments and carbon emissions data remain unspecified, reflecting a potential area for future development in sustainability practices.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 61,753,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,489.51 | 0,000.00 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | 000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 50% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Luminex Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.